Department of Medicine, Division of Infectious Diseases and Immunology
Immunity | Immunoprophylaxis and Therapy
In recent years, heterologous prime-boost vaccines have been demonstrated to be an effective strategy for generating protective immunity, consisting of both humoral and cell-mediated immune responses against a variety of pathogens including HIV-1. Previous reports of preclinical and clinical studies have shown the enhanced immunogenicity of viral vector or DNA vaccination followed by heterologous protein boost, compared to using either prime or boost components alone. With such approaches, the selection of an adjuvant for inclusion in the protein boost component is expected to impact the immunogenicity and safety of a vaccine. In this study, we examined in a mouse model the serum cytokine and chemokine profiles for several candidate adjuvants: QS-21, Al(OH)3, monophosphoryl lipid A (MPLA) and ISCOMATRIX adjuvant, in the context of a previously tested pentavalent HIV-1 Env DNA prime-protein boost formulation, DP6-001. Our data revealed that the candidate adjuvants in the context of the DP6-001 formulation are characterized by unique serum cytokine and chemokine profiles. Such information will provide valuable guidance in the selection of an adjuvant for future AIDS vaccine development, with the ultimate goal of enhancing immunogenicity while minimizing reactogenicity associated with the use of an adjuvant. More significantly, results reported here will add to the knowledge on how to include an adjuvant in the context of a heterologous prime-protein boost vaccination strategy in general.
Rights and Permissions
Copyright 2013 Buglione-Corbett et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
DOI of Published Version
Buglione-Corbett R, Pouliot K, Marty-Roix R, West K, Wang S, et al. (2013) Serum Cytokine Profiles Associated with Specific Adjuvants Used in a DNA Prime-Protein Boost Vaccination Strategy. PLoS ONE 8(9): e74820. doi:10.1371/journal.pone.0074820 Link to article on publisher's site
Buglione-Corbett R, Pouliot KL, Marty-Roix RL, West K, Wang S, Lien E, Lu S. (2013). Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy. Open Access Articles. https://doi.org/10.1371/journal.pone.0074820. Retrieved from https://escholarship.umassmed.edu/oapubs/2408